Venetoclax safe, shows promise in patients with acute myelogenous leukemia
Friday, August 12, 2016 - 09:01
in Health & Medicine
Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data.